Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

drug shortages

- PMLiVE

Succinct forms market access partnership with Royal Marsden

Agency aims is to tackle non-financial issues relating to new medicines

- PMLiVE

Janssen’s Zytiga approved for earlier use in Europe

Prostate cancer drug now licensed for use before chemotherapy

- PMLiVE

New EC anti-smoking plans include ban on flavoured tobacco

Pictorial health warnings on cigarettes and regulation for e-cigarettes also proposed

- PMLiVE

Boehringer takes leukaemia drug volasertib into phase III

Shows positive results in a difficult-to-treat patient population

- PMLiVE

ASH meeting hears of progress with myelofibrosis drugs

New studies suggest momentum is for use of Janus kinase (JAK) inhibitors

- PMLiVE

Pfizer reports strong data with new breast cancer candidate

Phase II results suggest progression-free survival benefits for PD-0332991

- PMLiVE

Pfizer launches personalised lung cancer drug Xalkori in UK

Becomes first treatment on the market for ALK-positive NSCLC

- PMLiVE

EMA publishes drug shortages plan

Globalisation of manufacturing among key issues to address

german flag

Pharma industry challenges Germany’s drug pricing policy

Says mandatory discounts and price freezes on drugs are no longer justified

- PMLiVE

India approves national drug pricing scheme

Adds around 350 new drugs to the country's essential medicines list

Drug pricing in Ireland

Sustained pressure on healthcare spending, combined with the continued impact of patent expiries, could thwart the pharma industry in Ireland

- PMLiVE

Astellas seeks FDA approval for personalised Tarceva in lung cancer

Application supported by Roche's EGFR companion diagnostic test

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links